Massimo Tempestilli
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data.
Journal: The Journal of antimicrobial chemotherapy
Published: February 17, 2026
Mpox virus in human breastmilk and tecovirimat pharmacokinetics: implications for postnatal transmission.
Journal: The Lancet. Infectious diseases
Published: January 29, 2026
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study).
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: March 11, 2025
Vδ2 T-cells response in people with Mpox infection: a three-month longitudinal assessment.
Journal: Emerging microbes & infections
Published: January 16, 2025
Innate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients.
Journal: International immunopharmacology
Published: July 22, 2024
Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study).
Journal: International journal of antimicrobial agents
Published: July 16, 2023
Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications.
Journal: The Lancet. Infectious diseases
Published: June 17, 2023
Tecovirimat concentrations and viral suppression in seminal fluid from patients with mpox.
Journal: The Lancet. Infectious diseases
Published: March 09, 2023
Pharmacokinetics of tecovirimat in subjects with Mpox.
Journal: International journal of antimicrobial agents
Published: January 30, 2023
Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
Journal: The Journal of antimicrobial chemotherapy
Published: March 31, 2022
Correction to: Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.
Journal: European journal of clinical pharmacology
Published: March 03, 2022
Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Journal: European journal of drug metabolism and pharmacokinetics
Published: September 19, 2021
Last Updated: 09/26/2026